[SCHEDULE 13G] Helix Acquisition Corp. II SEC Filing

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. is reported as having material passive ownership by multiple Deerfield entities and James E. Flynn. The filing states Deerfield Partners, Deerfield Private Design Fund V, Deerfield Mgmt, L.P. and Deerfield Mgmt V, L.P. each report ownership of 2,442,723 shares (3.08% of the class). Deerfield Management Company, L.P. and James E. Flynn each report aggregate beneficial ownership of 4,885,446 shares (6.17% of the class). All reporting persons state no sole voting or dispositive power and report shared voting and dispositive power only. The filing includes joint filing, item 8 exhibits, and a power of attorney.

Insights

Securities Analyst

TL;DR: Deerfield-affiliated entities disclose a combined >6% passive stake, signaling notable institutional interest without sole control.

The Schedule 13G shows coordinated reporting by multiple Deerfield vehicles and James E. Flynn, with 4,885,446 shares (6.17%) reported by Deerfield Management Company, L.P. and Mr. Flynn. The positions are reported as shared voting and dispositive power, with no sole control, and the filing certifies the holdings are not intended to change control. For investors, this is a material ownership disclosure reflecting institutional accumulation but characterized as passive under Section 13(d) rules.

Corporate Governance Expert

TL;DR: Ownership above 5% by an advisory/partner entity merits attention for potential influence despite passive filing.

The filing documents that Deerfield Management Company, L.P. and James E. Flynn each beneficially hold 6.17% of the common stock, reported via shared voting/dispositive power across affiliated funds. While the certification asserts no intent to influence control, the aggregated position and interlinked reporting entities could present a collective influence vector; however, the absence of sole voting or dispositive power limits immediate governance control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BridgeBio Oncology Therapeutics, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

107924102

(CUSIP Number)

08/11/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

Deerfield Mgmt, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,442,723.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,442,723.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,442,723.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.08 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

Deerfield Mgmt V, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,442,723.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,442,723.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,442,723.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.08 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Comprised of shares of common stock held by Deerfield Private Design Fund V, L.P., of which Deerfield Mgmt V, L.P. is the general partner.

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

Deerfield Partners, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,442,723.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,442,723.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,442,723.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.08 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

Deerfield Private Design Fund V, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,442,723.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,442,723.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,442,723.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.08 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

Deerfield Management Company, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,885,446.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,885,446.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,885,446.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.17 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., of which Deerfield Management Company, L.P. is the investment advisor.

SCHEDULE 13G

CUSIP No. 107924102

1

Names of Reporting Persons

James E. Flynn

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,885,446.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,885,446.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,885,446.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.17 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Comprised of shares of Common Stock held by Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BridgeBio Oncology Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 256 E. Grand Avenue, Suite 104, South San Francisco, CA 94080
Item 2.
(a)	Name of person filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt V, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P.
(b)	Address or principal business office or, if none, residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt V, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
(c)	Citizenship: Deerfield Mgmt, L.P., Deerfield Mgmt V, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield Private Design Fund V, L.P. - Delaware limited partnerships; James E. Flynn - United States citizen
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 107924102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Deerfield Mgmt, L.P. - 2,442,723 shares Deerfield Mgmt V, L.P. - 2,442,723 shares Deerfield Management Company, L.P. - 4,885,446 shares Deerfield Partners, L.P. - 2,442,723 shares Deerfield Private Design Fund V, L.P. - 2,442,723 shares James E. Flynn - 4,885,446 shares
(b)	Percent of class: Deerfield Mgmt, L.P. - 3.08% Deerfield Mgmt V, L.P. - 3.08% Deerfield Management Company, L.P. - 6.17% Deerfield Partners, L.P. - 3.08% Deerfield Private Design Fund V, L.P. - 3.08% James E. Flynn - 6.17%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: All Reporting Persons - 0
	(ii) Shared power to vote or to direct the vote: Deerfield Mgmt, L.P. - 2,442,723 Deerfield Mgmt V, L.P. - 2,442,723 Deerfield Management Company, L.P. - 4,885,446 Deerfield Partners, L.P. - 2,442,723 Deerfield Private Design Fund V, L.P. - 2,442,723 James E. Flynn - 4,885,446
	(iii) Sole power to dispose or to direct the disposition of: All Reporting Persons - 0
	(iv) Shared power to dispose or to direct the disposition of: Deerfield Mgmt, L.P. - 2,442,723 Deerfield Mgmt V, L.P. - 2,442,723 Deerfield Management Company, L.P. - 4,885,446 Deerfield Partners, L.P. - 2,442,723 Deerfield Private Design Fund V, L.P. - 2,442,723 James E. Flynn - 4,885,446
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit B
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Deerfield Mgmt, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	08/18/2025

Deerfield Mgmt V, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	08/18/2025

Deerfield Partners, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	08/18/2025

Deerfield Private Design Fund V, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	08/18/2025

Deerfield Management Company, L.P.

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	08/18/2025

James E. Flynn

Signature:	/s/ Jonathan Isler
Name/Title:	Jonathan Isler, Attorney-In-Fact
Date:	08/18/2025

Exhibit Information

Exhibit A. Joint Filing Agreement. Exhibit B. Item 8 Statement. Exhibit C. Power of Attorney (1). (1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund V, L.P., Deerfield Healthcare Innovations Fund II, L.P., Deerfield Mgmt V, L.P., Deerfield Mgmt HIF II, L.P., Deerfield Management Company, L.P. and James E. Flynn.

FAQ

How many shares of BridgeBio Oncology Therapeutics does Deerfield Management Company report owning?

Deerfield Management Company, L.P. reports beneficial ownership of 4,885,446 shares, representing 6.17% of the class.

What percentage of BridgeBio's common stock is reported by James E. Flynn?

James E. Flynn reports aggregate beneficial ownership of 4,885,446 shares, equal to 6.17% of the class.

Do the reporting persons claim sole voting or dispositive power over the shares?

No; all reporting persons state 0 shares of sole voting power and 0 shares of sole dispositive power, reporting only shared voting and dispositive power.

Are these holdings reported as intended to influence control of the issuer?

The filing includes a certification stating the securities were not acquired and are not held to change or influence control of the issuer.

Which Deerfield entities are listed as reporting persons in the Schedule 13G?

Reported entities include Deerfield Mgmt, L.P.; Deerfield Mgmt V, L.P.; Deerfield Management Company, L.P.; Deerfield Partners, L.P.; and Deerfield Private Design Fund V, L.P. and individual James E. Flynn.